EA201992742A3 - Применение cart19 для истощения нормальных b-клеток для индукции толерантности - Google Patents
Применение cart19 для истощения нормальных b-клеток для индукции толерантностиInfo
- Publication number
- EA201992742A3 EA201992742A3 EA201992742A EA201992742A EA201992742A3 EA 201992742 A3 EA201992742 A3 EA 201992742A3 EA 201992742 A EA201992742 A EA 201992742A EA 201992742 A EA201992742 A EA 201992742A EA 201992742 A3 EA201992742 A3 EA 201992742A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cart19
- cells
- application
- tolerance induction
- depleting
- Prior art date
Links
- 108010024755 CTL019 chimeric antigen receptor Proteins 0.000 title 1
- 230000000779 depleting effect Effects 0.000 title 1
- 230000024664 tolerance induction Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671508P | 2012-07-13 | 2012-07-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201992742A2 EA201992742A2 (ru) | 2020-09-30 |
| EA201992742A3 true EA201992742A3 (ru) | 2020-12-30 |
Family
ID=49916701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590209A EA034644B1 (ru) | 2012-07-13 | 2013-07-12 | Применение cart19 для истощения нормальных b-клеток для индукции толерантности |
| EA201992742A EA201992742A3 (ru) | 2012-07-13 | 2013-07-12 | Применение cart19 для истощения нормальных b-клеток для индукции толерантности |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590209A EA034644B1 (ru) | 2012-07-13 | 2013-07-12 | Применение cart19 для истощения нормальных b-клеток для индукции толерантности |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20150290244A1 (enExample) |
| EP (1) | EP2872184B1 (enExample) |
| JP (5) | JP2015523386A (enExample) |
| KR (1) | KR102216083B1 (enExample) |
| CN (2) | CN104884095A (enExample) |
| AU (3) | AU2013289984B2 (enExample) |
| BR (1) | BR112015000657B1 (enExample) |
| CA (1) | CA2876734A1 (enExample) |
| EA (2) | EA034644B1 (enExample) |
| ES (1) | ES2835232T3 (enExample) |
| IN (1) | IN2015DN00139A (enExample) |
| MX (2) | MX382772B (enExample) |
| WO (1) | WO2014012001A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| BR112015000657B1 (pt) * | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| FI3888674T3 (fi) | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| US11400115B2 (en) | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| WO2016028879A1 (en) * | 2014-08-19 | 2016-02-25 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating immune response |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| HK1258726A1 (zh) * | 2015-09-28 | 2019-11-15 | Regents Of The University Of Minnesota | 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预 |
| CN107531793B (zh) * | 2015-10-13 | 2022-01-11 | 优瑞科生物技术公司 | 对人类cd19具有专一性的抗体药剂和其用途 |
| JP2018536436A (ja) | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| KR20190003550A (ko) * | 2016-04-15 | 2019-01-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 키메라 동종항원 수용체 t 세포의 조성물 및 방법 |
| SI3443096T1 (sl) * | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| AU2017301887A1 (en) * | 2016-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies against anti-CD19 antibodies |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| WO2018102606A1 (en) * | 2016-11-30 | 2018-06-07 | Intrexon Corporation | Steroid administration and immunotherapy |
| EP3346001A1 (en) * | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| MX2019011272A (es) | 2017-03-22 | 2019-10-24 | Novartis Ag | Composiciones y metodos para inmunooncologia. |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| JP2021532116A (ja) * | 2018-07-23 | 2021-11-25 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用 |
| AU2019331009A1 (en) | 2018-08-31 | 2021-03-18 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| MX2022002342A (es) | 2019-08-30 | 2022-06-14 | Univ Yale | Composiciones y metodos para suministro de acidos nucleicos a celulas. |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| WO2021129015A1 (zh) * | 2019-12-27 | 2021-07-01 | 昭泰英基生物医药（香港）有限公司 | 工程化免疫杀伤细胞、其制备方法和应用 |
| WO2021142305A2 (en) * | 2020-01-10 | 2021-07-15 | Coimmune, Inc. | Methods of treating tumors |
| AU2021331785A1 (en) | 2020-08-31 | 2023-03-30 | Gennao Bio, Inc. | Compositions and methods for delivery of nucleic acids to cells |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
| CN120641131A (zh) | 2022-12-01 | 2025-09-12 | 耶鲁大学 | 用于细胞内有效载荷递送的刺激反应性无痕工程化平台 |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2587407A1 (en) * | 2004-11-17 | 2006-05-26 | Angiogen Pharmaceuticals Pty. Ltd. | A method of modulating b cell functioning |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| EP1795588A1 (en) * | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| RU2011140486A (ru) * | 2009-03-06 | 2013-04-20 | МЕДИММЬЮН, ЭлЭлСи | Композиции, содержащие гуманизированные антитела к cd19 |
| WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9133436B2 (en) * | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2651442B1 (en) * | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| BR112015000657B1 (pt) * | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
-
2013
- 2013-07-12 BR BR112015000657-4A patent/BR112015000657B1/pt active IP Right Grant
- 2013-07-12 AU AU2013289984A patent/AU2013289984B2/en active Active
- 2013-07-12 ES ES13816739T patent/ES2835232T3/es active Active
- 2013-07-12 CN CN201380037500.6A patent/CN104884095A/zh active Pending
- 2013-07-12 CN CN202510240499.1A patent/CN120393001A/zh active Pending
- 2013-07-12 EA EA201590209A patent/EA034644B1/ru not_active IP Right Cessation
- 2013-07-12 IN IN139DEN2015 patent/IN2015DN00139A/en unknown
- 2013-07-12 EP EP13816739.0A patent/EP2872184B1/en active Active
- 2013-07-12 MX MX2015000433A patent/MX382772B/es unknown
- 2013-07-12 CA CA2876734A patent/CA2876734A1/en active Pending
- 2013-07-12 US US14/413,100 patent/US20150290244A1/en not_active Abandoned
- 2013-07-12 EA EA201992742A patent/EA201992742A3/ru unknown
- 2013-07-12 JP JP2015521846A patent/JP2015523386A/ja not_active Withdrawn
- 2013-07-12 WO PCT/US2013/050293 patent/WO2014012001A2/en not_active Ceased
- 2013-07-12 KR KR1020157002826A patent/KR102216083B1/ko active Active
-
2015
- 2015-01-09 MX MX2018009820A patent/MX2018009820A/es unknown
-
2018
- 2018-04-23 JP JP2018082149A patent/JP2018135363A/ja not_active Withdrawn
- 2018-05-29 AU AU2018203756A patent/AU2018203756B2/en active Active
- 2018-06-04 US US15/996,667 patent/US20180271907A1/en not_active Abandoned
-
2020
- 2020-01-16 AU AU2020200315A patent/AU2020200315B2/en active Active
- 2020-07-01 JP JP2020113687A patent/JP2020158541A/ja not_active Withdrawn
-
2022
- 2022-09-22 JP JP2022150897A patent/JP2022173331A/ja active Pending
-
2023
- 2023-06-09 US US18/332,150 patent/US20240261328A1/en active Pending
-
2025
- 2025-07-04 JP JP2025113498A patent/JP2025129358A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992742A2 (ru) | Применение cart19 для истощения нормальных b-клеток для индукции толерантности | |
| EA201390847A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| TR201905458T4 (tr) | Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri. | |
| IN2014DN07414A (enExample) | ||
| EA201391609A1 (ru) | Толерогенные синтетические наноносители для индукции регуляторных b-клеток | |
| MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
| IN2014DN11155A (enExample) | ||
| MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| IN2014DN06522A (enExample) | ||
| IN2014MN01879A (enExample) | ||
| MX374929B (es) | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. | |
| PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
| MX2013002173A (es) | Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos. | |
| WO2013054199A3 (en) | Cmv antigens and uses thereof | |
| MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
| WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
| MX2014010754A (es) | Composiciones que comprenden inmunoglobulinas de tipo secretor. | |
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| EP2812028A4 (en) | EPITOPES OF ALLERGENIC PROTEINS AND METHOD AND USE TO IMMUNE REACTION MODULATION | |
| MX2013009529A (es) | Tratamiento de enfermedad de crohn con fistulas. | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| CU20130079A7 (es) | Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer |